New targets for the treatment of follicular lymphoma

Journal of Hematology and Oncology

Volumn 2, Issue , 2009, Pages

  Tageja, Nishant ^a   Padheye, Subhash ^b   Dandawate, Prasad ^b   Al Katib, Ayad ^a   Mohammad, Ramzi M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DR D Y PATIL DENTAL COLLEGE AND HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXEN 1 YLMETHYL] 1 PIPERAZINYL] N [4 [3 MORPHOLINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONYL]BENZAMIDE; ANTINEOPLASTIC AGENT; APOGOSSYPOL; BORTEZOMIB; DOXORUBICIN; MI 219; MI 319; NUTLIN 1; NUTLIN 2; NUTLIN 3; PACLITAXEL; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53; RAPAMYCIN; THYMOQUINONE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

CANCER CELL CULTURE; CANCER REGRESSION; CANCER RELAPSE; DRUG MECHANISM; DRUG STRUCTURE; FOLLICULAR LYMPHOMA; HUMAN; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; SURVIVAL TIME; ANIMAL; APOPTOSIS; BIOLOGICAL MODEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; EVALUATION; METHODOLOGY; ONCOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG DELIVERY SYSTEMS; HUMANS; LYMPHOMA, FOLLICULAR; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION;

EID: 75149125289     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-2-50     Document Type: Review

References (127)

1. Cancer Statistics, 2008. A Jemal R Siegel E Ward, et al. CA Cancer J Clin 2008 58 71 96 10.3322/CA.2007.0010 18287387
2. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. JO Armitage DD Weisenburger, J Clin Oncol 1998 16 8 2780 95 9704731
3. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. NL Harris ES Jaffe J Diebold, et al. J Clin Oncol 1999 17 12 3835 49 10577857
4. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis. H Schulz JF Bohlius S Trelle, et al. J Natl Can Inst 2007 99 706 14 10.1093/jnci/djk152 (Pubitemid 47078732)
5. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. P McLaughlin AJ Grillo-Lápez BK Link, et al. J Clin Oncol 1998 16 2825 33 9704735
6. Higher-grade transformation of follicular lymphoma - a continuous enigma. IS Lossos, Leukemia 2005 19 8 1331 3 10.1038/sj.leu.2403801 15902286
7. Cell death: the significance of apoptosis. AH Wyllie JFR Kerr AR Currie, Int Rev Cytol 1980 68 251 10.1016/S0074-7696(08)62312-8 7014501
8. Death Receptors- Signaling and Modulation. A Ashkenazi VM Dixit, Science 1998 281 1305 10.1126/science.281.5381.1305 9721089
9. Capases: cellular demolition experts. EM Creagh SJ Martin, Biochem Soc Trans 2001 29 696 10.1042/BST0290696 11709057
10. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. P Li D Nijhawan I Budihardjo, et al. Cell 1997 91 4 479 89 10.1016/S0092-8674(00)80434-1 9390557
11. Caspase Mechanisms. GS Salvesen SJ Riedl, Adv Exp Med Biol 2008 615 13 23 full-text 18437889
12. Post-embryonic cell lineages of the nematode, Caenorhabditis elegans. JE Sulston HR Horvitz, Dev Biol 1977 56 1 110 56 10.1016/0012-1606(77)90158-0 838129
13. Caenorhabditis elegans gene ced-9 protects cells from programmed cell death. MO Hengartner RE Ellis HR Horvitz, Nature 1992 356 6369 494 9 10.1038/356494a0 1560823
14. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. DL Vaux S Cory JM Adams, Nature 1988 335 6189 440 21 10.1038/335440a0 3262202
15. The Bcl2 family: regulators of the cellular life-or-death switch. S Cory JM Adams, Nat Rev Cancer 2002 2 9 647 56 Review 10.1038/nrc883 12209154
16. A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. T Chittenden C Flemington AB Houghton RG Ebb GJ Gallo, et al. EMBO J 1995 14 22 5589 96 8521816
17. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. A Letai MC Bassik LD Walensky MD Sorcinelli S Weiler SJ Korsmeyer, Cancer Cell 2002 2 3 183 92 10.1016/S1535-6108(02)00127-7 12242151
18. Bcl-2-family proteins: the role of the BH3 domain in apoptosis. A Kelekar CB Thompson, Trends Cell Biol 1998 8 8 324 30 10.1016/S0962-8924(98)01321-X 9704409
19. The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4. DC Huang JM Adams S Cory, EMBO J 1998 17 4 1029 39 10.1093/emboj/17.4.1029 9463381
20. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. TW Sedlak ZN Oltvai E Yang K Wang LH Boise, et al. Proc Natl Acad Sci USA 1995 92 17 7834 8 10.1073/pnas.92.17.7834 7644501
21. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. SJ Korsmeyer JR Shutter DJ Veis DE Merry ZN Oltvai, Semin Cancer Biol 1993 4 6 327 32 8142617
22. BAD, a heterodimeric partner for Bcl-XL and Bcl-2, displaces BAX and promotes cell death. E Yang J Zha J Jockel, et al. Cell 1995 80 2 285 91 10.1016/0092-8674(95)90411-5 7834748
23. BH3 domain of BAD is required for heterodimerization with BCL-XL and pro-apoptotic activity. J Zha H Harada K Osipov, et al. J Biol Chem 1997 272 39 24101 4 10.1074/jbc.272.39.24101 9305851
24. Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. D Acehan X Jiang DG Morgan JE Heuser, et al. Mol Cell 2002 9 2 423 432 10.1016/S1097-2765(02)00442-2 11864614
25. An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. H Zou Y Li X Liu X Wang, J Biol Chem 1999 274 17 11549 56 10.1074/jbc.274.17.11549 10206961
26. The BH3 domain is required for caspase-independent cell death induced by Bax and oligomycin. ME Fitch CM Chang TG Parslow, Cell Death Differ 2000 7 4 338 49 10.1038/sj.cdd.4400659 10773818
27. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Y Tsujimoto LR Finger J Yunis PC Nowell CM Croce, Science 1984 226 4678 1097 9 10.1126/science.6093263 6093263
28. Cloning the chromosomal breakpoint of t(14;18) of human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. A Bakshi JP Jensen P Goldman, et al. Science 1099 226 1097 1984
29. Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma. RJ Klasa, Oncology (Williston Park) 2004 18 25 31 15651174
30. Antisense-mediated inhibition of BCL2 proto-oncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. JC Reed C Stein C Subasinghe, et al. Cancer Res 1990 50 6565 6570 2208117
31. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. S O'Brien JO Moore TE Boyd LM Larratt A Skotnicki, et al. J Clin Oncol 2008 26 5 820
32. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. LD Walensky AL Kung I Escher TJ Malia S Barbuto, et al. Science 2004 305 5689 1466 70 10.1126/science.1099191 15353804
33. A membrane-targeted BID BCL-2 homology 3 peptide is sufficient for high potency activation of BAX in vitro. KJ Oh S Barbuto K Pitter J Morash LD Walensky, et al. J Biol Chem 2006 281 48 36999 7008 10.1074/jbc.M602341200 16987815
34. Rational design and real time in-cell detection of the pro-apoptotic activity of a novel compound targeting Bcl-Xl. B Becattini S Kitada M Leone, et al. Chem Biol 2004 11 389 395 10.1016/j.chembiol.2004.02.020 15123268
35. Anti-fertility and other actions of gossypol analogues. M Sonenberg JT Huang YF Ren TL Su KA Watanabe, et al. Contraception 1988 37 3 247 55 10.1016/0010-7824(88)90027-3 3370997
36. Comparison of chemical inhibitors of anti-apoptotic Bcl-2-family proteins. D Zhai C Jin AC Satterthwait JC Reed, Cell Death Differ 2006 13 1419 1421 10.1038/sj.cdd.4401937 16645636
37. Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). S Kitada CL Kress M Krajewska L Jia M Pellecchia, et al. Blood 2008 111 6 3211 3219 10.1182/blood-2007-09-113647 18202226
38. Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model. AA Arnold A Aboukameel J Chen D Yang S Wang, et al. Mol Cancer 2008 7 20 10.1186/1476-4598-7-20 18275607
39. A unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8;11). RM Mohammad AN Mohamed MR Smith NS Jawadi A al-Katib, Cancer Genet Cytogenet 1993 70 62 67 10.1016/0165-4608(93)90132-6 8221615
40. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. T Oltersdorf SW Elmore AR Shoemaker RC Armstrong DJ Augeri, et al. Nature 2005 435 7042 677 81 10.1038/nature03579 15902208
41. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. MF van Delft AH Wei KD Mason CJ Vandenberg L Chen, et al. Cancer Cell 2006 10 5 389 99 10.1016/j.ccr.2006.08.027 17097561
42. Killing cancer cells by flipping the Bcl-2/Bax switch. S Cory JM Adams, Cancer Cell 2005 8 1 5 6 10.1016/j.ccr.2005.06.012 16023593
43. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. AM Petros J Dinges DJ Augeri SA Baumeister DA Betebenner, et al. J Med Chem 2006 49 2 656 63 10.1021/jm0507532 16420051
44. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. C Tse AR Shoemaker J Adickes MG Anderson J Chen, et al. Cancer Res 2008 68 9 3421 8 10.1158/0008-5472.CAN-07-5836 18451170
45. ABT 263: an orally available bcl-2 family protein inhibitor. SW Elmore, Proceedings AACR 2007
46. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. AR Shoemaker MJ Mitten J Adickes S Ackler M Refici, et al. Clin Cancer Res 2008 14 11 3268 77 10.1158/1078-0432.CCR-07-4622 18519752
47. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. CM Park M Bruncko J Adickes J Bauch H Ding, et al. J Med Chem 2008 51 21 6902 15 Epub 2008 Oct 8 10.1021/jm800669s 18841882
48. ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. S Ackler Y Xiao MJ Mitten K Foster A Oleksijew, et al. Mol Cancer Ther 2008 7 10 3265 74 10.1158/1535-7163.MCT-08-0268 18852130
49. A phase 1/2a study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with Refractory or Relapsed Lymphoid Malignancies. WH Wilson A Tulpule AM Levine, et al. Blood (ASH Annual Meeting Abstracts) 2007 110 1371
50. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. JL Wang D Liu ZJ Zhang S Shan X Han, et al. Proc Natl Acad Sci 2000 97 13 7124 7129 10.1073/pnas.97.13.7124 10860979
51. Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. JB Baell DCS Huang, Biochem Pharmacol 2002 64 5-6 851 63 10.1016/S0006-2952(02)01148-6 12213579
52. HA14-1, a small molecule Bcl-2 antagonist, induces apoptosis and modulates action of selected anticancer drugs in follicular lymphoma B cells. J Skommer D Wlodkowic M Mättö M Eray J Pelkonen, Leuk Res 2006 30 3 322 31 10.1016/j.leukres.2005.08.022 16213584
53. Multiparametric analysis of HA14-1-induced apoptosis in follicular lymphoma cells. D Wlodkowic J Skommer J Pelkonen, Leuk Res 2006 30 9 1187 92 10.1016/j.leukres.2005.11.024 16414117
54. Brefeldin A triggers apoptosis associated with mitochondrial breach and enhances HA14-1- and anti-Fas-mediated cell killing in follicular lymphoma cells. D Wlodkowic J Skommer J Pelkonen, Leuk Res 2007 31 12 1687 700 10.1016/j.leukres.2007.03.008 17428536
55. Control of apoptosis by p53. JS Fridman SW Lowe, Oncogene 2003 22 56 9030 40 10.1038/sj.onc.1207116 14663481
56. p53 and human cancer: the first ten thousand mutations. P Hainaut M Hollstein, Adv Cancer Res 2000 77 81 137
57. Surfing the p53 network. B Vogelstein D Lane AJ Levine, Nature 2000 408 6810 307 10 10.1038/35042675 11099028
58. Targeting the MDM2-p53 interaction for cancer therapy. S Shangary S Wang, Clin Cancer Res 2008 14 17 5318 24 10.1158/1078-0432.CCR-07-5136 18765522
59. Mutational spectrum of p53 mutations in primary breast and ovarian tumors. A Feki I Irminger-Finger, Crit Rev Oncol Hematol 2004 52 2 103 16 10.1016/j.critrevonc.2004.07.002 15501075
60. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. J Momand GP Zambetti DC Olson D George AJ Levine, Cell 1992 69 1237 45 10.1016/0092-8674(92)90644-R 1535557
61. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. SS Fakharzadeh SP Trusko DL George, EMBO J 1991 10 1565 69 2026149
62. Structure and organization of amplified DNA on double minutes containing the mdm2 oncogene. SS Fakharzadeh L Rosenblum-Vos M Murphy EK Hoffman DL George, Genomics 1993 15 283 90 10.1006/geno.1993.1058 8449492
63. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. SN Jones AE Roe LA Donehower A Bradley, Nature 1995 378 206 8 10.1038/378206a0 7477327
64. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. R Montes de Oca Luna DS Wagner G Lozano, Nature 1995 378 203 6 10.1038/378203a0 7477326
65. mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. SM Mendrysa MK McElwee J Michalowski KA O'Leary KM Young ME Perry, Mol Cell Biol 2003 23 462 72 10.1128/MCB.23.2.462- 473.2003 12509446
66. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. PH Kussie S Gorina V Marechal B Elenbaas J Moreau, et al. Science 1996 274 948 53 10.1126/science.274.5289.948 8875929
67. Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. LT Vassilev, Cell Cycle 2004 3 419 21 15004525
68. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. K Ding Y Lu Z Nikolovska-Coleska G Wang S Qiu, et al. J Med Chem 2006 49 3432 35 10.1021/jm051122a 16759082
69. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. S Shangary D Qin D McEachern M Liu RS Miller, et al. Proc Natl Acad Sci USA 2008 105 10 3933 8 10.1073/pnas.0708917105 18316739
70. mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. SM Mendrysa MK McElwee J Michalowski KA O'Leary KM Young, et al. Mol Cell Biol 2003 23 2 462 72 10.1128/MCB.23.2.462- 473.2003 12509446
71. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. I Ringshausen CC O'Shea AJ Finch LB Swigart GI Evan, Cancer Cell 2006 10 501 14 10.1016/j.ccr.2006.10.010 17157790
72. Development of the proteasome inhibitor PS-341. J Adams, Oncologist 2002 7 9 16 10.1634/theoncologist.7-1-9 11854543
73. The ubiquitin-proteasome proteolytic pathway. A Ciechanover, Cell 1994 79 13 21 10.1016/0092-8674(94)90396-4 7923371
74. The ubiquitin system. A Varshavsky, Trend Biochem Sci 1997 22 383 387 10.1016/S0968-0004(97)01122-5 9357313
75. The multicatalytic proteinase complex, a major extralysosomal proteolytic system. M Orlowski, Biochemistry 1990 29 10289 10297 10.1021/bi00497a001 2175651
76. Structure and functions of the 20S and 26S proteasomes. O Coux K Tanaka AL Goldberg, Annu Rev Biochem 1996 65 801 847 10.1146/annurev.bi.65.070196. 004101 8811196 (Pubitemid 26255262)
77. The proteasome: A novel target for cancer chemotherapy. JB Almond GM Cohen, Leukemia 2002 16 433 443 10.1038/sj.leu.2402417 11960320
78. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. B An RH Goldfarb R Siman, et al. Cell Death Differ 1998 5 1062 1075 10.1038/sj.cdd.4400436 9894613
79. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. RZ Orlowski JR Eswara A Lafond-Walker, et al. Cancer Res 1998 58 4342 4348 9766662
80. Development of the proteasome inhibitor velcade (bortezomib). J Adams M Kauffman, Cancer Invest 2004 22 304 11 10.1081/CNV-120030218 15199612
81. Proteasome inhibition: a new strategy in cancer treatment. J Adams VJ Palombella PJ Elliott, Invest New Drugs 2000 18 109 21 10.1023/A:1006321828515 10857991
82. The proteasome, a novel protease regulated by multiple mechanisms. GN DeMartino CA Slaughter, J Biol Chem 1999 274 22123 6 10.1074/jbc.274.32.22123 10428771
83. Proteasome inhibitors: from research tools to drug candidates. AF Kisselev AL Goldberg, Chem Biol 2001 8 739 58 10.1016/S1074-5521(01)00056-4 11514224
84. Proteasome inhibitors: a novel class of potent and effective antitumor agents. J Adams VJ Palombella EA Sausville J Johnson A Destree DD Lazarus J Maas CS Pien S Prakash PJ Elliott, Cancer Res 1999 59 2615 22 10363983
85. The ubiquitin-proteasome pathway and proteasome inhibitors. J Myung KB Kim CM Crews, Med Res Rev 2001 21 245 73 10.1002/med.1009 11410931
86. The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells. H Matta PM Chaudhary, Cancer Biol Ther 2005 4 77 82 15662128
87. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. J An Y Sun M Fisher MB Rettig, Leukemia 2004 18 1699 704 10.1038/sj.leu.2403460 15343345
88. Mantle cell and follicular lymphoma samples demonstrate differeing sensitivity to bortezomib in a primary culture system. L Maharaj S Strauss J Stec T Lister S Joel, Blood 2004 104 900
89. Antitumor activity of the proteasome inhibitor PS-341 in mantle cell lymphoma B cells. L Pham AT Tamayo P Lo L Yoshimura R Ford, Blood 2001 98 465
90. Sensitivity, schedule-dependence and molecular effects of the proteasome inhibitor bortezomib in non-Hodgkin's lymphoma cells. A Goy Y Remache B Barkoh Y Jiang S Hart F Gilles, Blood 2004 104 389a 90a
91. Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): preliminary results of the PINNACLE study. A Goy S Bernstein B Kahl E Epner JP Leonard E Stadtmauer D Morgan R Belt S Baidas RI Fisher, J Clin Oncol 2005 23 6563 10.1200/JCO.2005.03.108 (Pubitemid 46224166)
92. A multicenter experience with single agent bortezomib in non-Hodgkin's lymphoma reveals marked differences in sub-type sensitivity to proteasome inhibition. O O'Connor J Wright C Moskowitz B MacGregor-Cortelli D Straus A Evans J Winter O Koc N Horvath S Blumel J Vose D Schenkein, et al. Blood 2004 104 175
93. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. A Goy A Younes P McLaughlin B Pro JE Romaguera F Hagemeister L Fayad NH Dang F Samaniego M Wang K Broglio B Samuels, et al. J Clin Oncol 2005 23 667 75 10.1200/JCO.2005.03.108 15613697
94. Phase II clinical study of bortezomib (velcade) in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). SJ Strauss L Maharaj J Stec A Boral E Trehu D Schenkein P Johnson SP Joel L TA, Blood 2004 104 10.1182/blood-2004-04-1311 (Pubitemid 39564416)
95. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. JP Sheridan SA Marsters RM Pitti, et al. Science 1997 277 818 821 10.1126/science.277.5327.818 9242611
96. Caspases: Enemies within. NA Thornberry Y Lazebnik, Science 1998 281 1312 1316 10.1126/science.281.5381.1312 9721091
97. Variable distribution of TRAIL Receptor 1 in primary human tumor and normal tissues. W Halpern C Lincoln A Sharifi, et al. Eur J Cancer 2004 2 69
98. Cutting edge: TRAIL deficiency accelerates hematological malignancies. N Zerafa JA Westwood E Cretney S Mitchell P Waring, et al. J Immunol 2005 175 9 5586 90 16237043
99. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. DJ Buchsbaum T Zhou WE Grizzle PG Oliver CJ Hammond, et al. Clin Cancer Res 2003 9 10 Pt 1 3731 41 14506165
100. Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody. H Kim DE Morgan H Zeng WE Grizzle JM Warram, et al. Radiology 2008 248 3 844 51 10.1148/radiol. 2483071740 18710978
101. CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-kappaB activation and up-regulation of c-FLIP and Bcl-xL. M Travert P Ame-Thomas C Pangault A Morizot O Micheau, et al. J Immunol 2008 181 2 1001 11 18606651
102. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. AW Tolcher M Mita NJ Meropol M von Mehren A Patnaik, et al. J Clin Oncol 2007 25 29 4701 10.1200/JCO.2007.14.0996 (Pubitemid 350035342)
103. Results of a Phase 2 trial of HGS-ETR1(agonist human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/refractory non-Hodgkin's lymphoma (NHL). A Younes JM Vose AD Zelenetz, et al. Blood 2005 106 146
104. "Activation and suppression of the TRAIL death-receptor pathway in chemotherapy sensitive and resistant follicular lymphoma cells". KW Wagner F King K Nomoto DA Knee G Hampton M Nasoff QL Deveraux, Cancer Biol Ther. 2003 2 5 534 540
105. From here to eternity - the secret of Pharaohs: Therapeutic potential of black cumin seeds and beyond. S Padhye S Banerjee A Ahmad R Mohammad FH Sarkar, Cancer Ther 2008 6 b 495 510 19018291
106. Oral and intraperitoneal LD50 of thymoquinone, an active principle of Nigella sativa, in mice and rats. A Al-Ali AA Alkhawajah MA Randhawa NA Shaikh, J Ayub Med Coll Abbottabad 2008 20 2 25 7 19385451
107. In vitro inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone. AM Shoieb M Elgayyar PS Dudrick JL Bell PK Tithof, Int J Oncol 2003 22 107 113 12469192
108. Checkpoints: controls that ensure the order of cell cycle events. LH Hartwell TA Weinert, Science 1989 246 629 634 10.1126/science.2683079 2683079
109. Cell cycle control and cancer. LH Hartwell MB Kastan, Science 1994 266 1821 1828 10.1126/science.7997877 7997877
110. Molecular pathway for thymoquinone-induced cell-cycle arrest and apoptosis in neoplastic keratinocytes. HU Gali-Muhtasib WG bou Kheir LA Kheir N Darwiche PA Crooks, Anticancer Drugs 2004 15 389 399 10.1097/00001813-200404000- 00012 15057144
111. WAF1, a potential mediator of p53 tumor suppression. WS el-Deiry T Tokino VE Velculescu DB Levy R Parsons JM Trent D Lin WE Mercer KW Kinzler B Vogelstein, Cell 1993 75 817 825 10.1016/0092-8674(93)90500-P 8242752
112. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. E Yonish-Rouach D Resnitzky J Lotem L Sachs A Kimchi M Oren, Nature 1991 352 345 347 10.1038/352345a0 1852210
113. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. P Shaw R Bovey S Tardy R Sahli B Sordat J Costa, Proc Natl Acad Sci USA 1992 89 4495 4499 10.1073/pnas.89.10.4495 1584781
114. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. H Hermeking C Lengauer K Polyak TC He L Zhang S Thiagalingam KW Kinzler B Vogelstein, Mol Cell 1997 1 3 11 10.1016/S1097-2765(00)80002-7 9659898
115. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. F Bunz A Dutriaux C Lengauer T Waldman S Zhou JP Brown JM Sedivy KW Kinzler B Vogelstein, Science 1998 282 1497 1501 10.1126/science.282.5393.1497 9822382
116. Lack of p53 augments thymoquinone-induced apoptosis and caspase activation in human osteosarcoma cells. M Roepke A Diestel K Bajbouj D Walluscheck P Schonfeld A Roessner R Schneider-Stock H Gali-Muhtasib, Cancer Biol Ther 2007 6 160 169 17218778
117. Role of the RB tumor suppressor in cancer. L Yamasaki, Cancer Treat Res 2003 115 209 239 full-text 12613199
118. Molecular pathway for thymoquinone-induced cell-cycle arrest and apoptosis in neoplastic keratinocytes. HU Gali-Muhtasib WG bou Kheir LA Kheir N Darwiche PA Crooks, Anticancer Drugs 2004 15 389 399 10.1097/00001813-200404000- 00012 15057144
119. Thymoquinone induces apoptosis through activation of caspase-8 and mitochondrial events in p53-null myeloblastic leukemia HL-60 cells. MA El-Mahdy Q Zhu QE Wang G Wani AA Wani, Int J Cancer 2005 117 409 417 10.1002/ijc.21205 15906362
120. Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. AO Kaseb K Chinnakannu D Chen A Sivanandam S Tejwani M Menon QP Dou GP Reddy, Cancer Res 2007 67 7782 7788 10.1158/0008-5472.CAN-07-1483 17699783
121. Potential of Spice-Derived Phytochemicals for Cancer Prevention. BB Aggarwal AB Kunnumakkara KB Harikumar ST Tharakan BA Sung, Planta Med 2008 74 13 1560 9 10.1055/s-2008-1074578 18612945
122. Targeting Nuclear Factor-{kappa}B Activation Pathway by Thymoquinone: Role in Suppression of Antiapoptotic Gene Products and Enhancement of Apoptosis. G Sethi KS Ahn BB Aggarwal, Mol Cancer Res 2008 6 1059 1070 10.1158/1541-7786.MCR-07-2088 18567808
123. Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. G Sethi KS Ahn BB Aggarwal, Mol Cancer Res 2008 6 6 1059 70 10.1158/1541-7786.MCR- 07-2088 18567808
124. Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells. N Chehl G Chipitsyna Q Gong CJ Yeo HA Arafat, HPB (Oxford) 2009 11 5 373 81 19768141
125. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. S Banerjee AO Kaseb Z Wang D Kong M Mohammad S Padhye FH Sarkar RM Mohammad, Cancer Res 2009 69 13 5575 83 10.1158/0008-5472.CAN-08-4235 19549912
126. Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. T Yi SG Cho Z Yi X Pang M Rodriguez Y Wang G Sethi BB Aggarwal M Liu, Mol Cancer Ther 2008 7 7 1789 96 10.1158/1535-7163.MCT-08-0124 18644991
127. Thymoquinone Triggers Inactivation of the Stress Response Pathway Sensor CHEK1 and Contributes to Apoptosis in Colorectal Cancer Cells. H Gali-Muhtasib D Kuester C Mawrin K Bajbouj A Diestel M Ocker C Habold C Foltzer-Jourdainne P Schoenfeld B Peters M ab-Assaf U Pommrich W Itani H Lippert A Roessner R Schneider-Stock, Cancer Res 2008 68 5609 5618 10.1158/0008-5472.CAN-08-0884 18632613